Interventional Glaucoma

NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and the role of microshunts in glaucoma surgery.

Andrew Tatham, MD, MBA, FRCOphth, FEBO, outlines the role of micro-invasive glaucoma surgery alongside established glaucoma procedures, focusing on safety, patient selection, and future directions.

AI is reshaping clinical practice in retinal imaging and workflow optimization, according to Priv.-Doz. Dr. med. Jan H. Terheyden, FEBO.

Prof. Dr. med. Wolf A. Lagrèze highlights the clinical role, limitations, and future potential of optical coherence tomography in glaucoma and neuro-ophthalmic disease.

Commercial OCT maps five IPL sublayers; aging reduces contrast, hinting at earlier biomarkers for glaucoma and Alzheimer’s.

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

Optometrists track 2026 breakthroughs in dry eye therapies, AI-powered screening and referrals, and genetics-driven glaucoma risk tools that reshape patient care.

James Tsai, MD, MBA, sheds light on what is in the offing for glaucoma specialists

James Tsai, MD, MBA, discusses his approaches given the wide diversity of patients in a major urban setting when awareness of glaucoma can range from highly educated patients to uninformed individuals.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

From artificial intelligence to home monitoring, Joel Schuman, MD, of Wills Eye Hospital, explores the innovations that could change how clinicians detect and treat glaucoma in the new year.

NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, exposure duration, and thermal spread in a simulated ciliary body using computer modeling.

The trial is evaluating the company’s femtosecond laser trabeculotomy procedure in comparison to selective laser trabeculoplasty

The SAPPHIRE trial evaluating the VisiPlate is currently underway across several sites across the US, with more site activations scheduled for 2026